CANDiD · PLOS ONE · 2022
Cancer detection across 30 cancer types
Clinical validation in 1,100 dogs detected cancer signals across 30 cancer types.
Read the study ↗FOR VETERINARY TEAMS
Liquid biopsy.
For canine cancer care.
Canos liquid biopsy tests analyse cancer signals in blood, helping vets assess disease and follow changes through treatment and follow-up.
VETERINARY GUIDANCE & EVIDENCE
Liquid biopsy in veterinary care.
Professional guidance and canine studies cover cancer detection, test interpretation and monitoring through care.
- RCVS Knowledge ↗
Evidence collection · 2025
- AAHA oncology guidelines ↗
Liquid biopsy & precision diagnostics · 2026
- NC State veterinary oncologists ↗
Clinical review · Today’s Veterinary Practice · 2024 (PDF)
HUMAN CLINICAL PROGRESS
Already guiding cancer care.
Liquid biopsy already helps guide treatment decisions in human cancers.
- ASCO ctDNA guideline ↗
Solid tumours & lymphoma · 2026
- ESMO recommendations ↗
ctDNA testing for treatment selection · 2022
- FDA-authorised companion diagnostics ↗
Blood-based tests linked to cancer treatments
FROM YOUR CLINIC TO OUR LAB
Three simple steps.
We handle the rest.
Receive your kit
Collection tubes and clear instructions, supplied by Canos.
Take the blood sample
A routine draw. No on-site processing.
Ship to our lab
Pack the sample and follow the kit’s shipping instructions.
We process the sample and prepare the report. Follow the supplied protocol for collection, handling and shipping. Download blood collection protocol (PDF)
CANOS × NY VET SHOW
Veterinary survey.
Complete our short survey and collect your Canos towel.
7 questions · Your perspective on cancer care
THE CANOS TESTS
Different questions.
A molecular perspective.
CANCER DETECTION + HEALTH BASELINE
Origin
Detect cancer-associated signals in blood and record genetics, epigenetics and cfDNA as a comprehensive genomic health baseline for future reference.
Explore OriginCANCER SCREENING
Guardian
The cancer screening part of Origin as a focused test: cell-free DNA analysis, multi-cancer screening and a cancer screening report.
Explore GuardianMRD MONITORING
OncoTrack
Minimal residual disease (MRD) monitoring: follow cancer-associated signals through treatment and follow-up.
Explore OncoTrackIN PRACTICE
How Canos supports
clinical decision-making.
01
Detect cancer signals. Establish a baseline.
Origin combines cancer signal detection with genetics, epigenetics and cfDNA analysis to establish a comprehensive molecular health baseline.
02
Monitor therapeutic response
Track molecular changes between imaging visits to evaluate treatment response as therapy progresses.
03
Monitor residual disease and recurrence
Track cancer-associated signals after treatment and follow molecular changes through remission.
04
Screen for cancer
Guardian brings the search for signals from multiple cancer types into one blood-based test.
CANINE CLINICAL STUDIES
Detection. Treatment. Follow-up.
JAVMA · 2023
Experience from 1,500 clinical cases
Veterinary practices used blood-based testing for cancer screening and to aid diagnosis. The study reports clinical performance and diagnostic follow-up in routine care.
Read the study ↗AMERICAN JOURNAL OF VETERINARY RESEARCH · 2024
Residual disease and recurrence
Post-surgical cancer signals were associated with recurrence. Serial blood tests detected molecular recurrence before clinical recurrence in six dogs.
Read the study ↗COMMUNICATIONS MEDICINE · 2026
Molecular changes through treatment
Liquid biopsy measures tracked disease status during treatment. Increases in molecular measures were observed before clinical relapse in dogs with lymphoma and osteosarcoma.
Read the study ↗COMMON QUESTIONS
For clinics and mobile vets.
